Pioglitazon – aktualna ocena skuteczności i bezpieczeństwa w terapii cukrzycy typu 2 Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
mar 31, 2012
Słowa kluczowe:
cukrzyca typu 2, pioglitazon, doustne leki przeciwcukrzycowe
##plugins.themes.bootstrap3.article.main##
Abstrakt
Liczba przypadków cukrzycy typu 2 systematycznie wzrasta. Do rozwoju hiperglikemii przyczyniają się się narastająca insulinooporność i dysfunkcja komórek beta. Pioglitazon jest przedstawicielem tiazolidynedionów, grupy leków, które zmniejszają insulinooporność. Jest skuteczny w monoterapii oraz w leczeniu skojarzonym z innymi lekami przeciwcukrzycowymi. Najskuteczniej działa w połączeniu z metforminą oraz u osób z nadmierną masą ciała. Ryzyko hipoglikemii związane z jego stosowaniem jest niskie, korzystnie wpływa na profil lipidowy, nie powoduje wzrostu ryzyka powikłań sercowo-naczyniowych. Do najczęstszych objawów niepożądanych należą: wzrost masy ciała, retencja płynów, nasilenie objawów niewydolności krążenia, złamania kości (zwłaszcza u kobiet). Obecny stan wiedzy wskazuje, że korzyści ze stosowania pioglitazonu przeważają nad zagrożeniem działaniami niepożądanymi.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Pawłowski, M., & Czupryniak, L. (2012). Pioglitazon – aktualna ocena skuteczności i bezpieczeństwa w terapii cukrzycy typu 2 . Medycyna Faktów , 5(1(14), 10-15. Pobrano z https://journalsmededu.pl/index.php/jebm/article/view/2473
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Wild S., Roglic G., Green A. et al.: Global Prevalence of Diabetes Estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-1053.
2. Wittek A., Sokalski B., Grzeszczak W. et al.: Prevalence of Diabetes and Cardiovascular Risk Factors of Industrial Area in Southern Poland. Exp. Clin. Endocrinol. Diabetes 2009; 117: 350-353.
3. De Fronzo R.A.: From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes. Mellitus Diabetes 2009; 58: 773-795.
4. Sieradzki J.: Cukrzyca. Via Medica 2006.
5. Moczulski D.: Diabetologia. Medical Tribune 2010.
6. Questions and answers on the suspension of rosiglitazone-containing medicines [online].
7. Yki-Järvinen H.: Thiazolidinediones. N. Engl. J. Med. 2004; 351(11): 1106-18.
8. Hallakou S., Doare L., Foufelle F. et al.: Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat. Diabetes 1997; 46: 1393-9.
9. Eckland D.A., Danhof M.: Clinical pharmacokinetics of pioglitazone. Exp. Clin. Endocrinol. Diabetes 2000; 108(supl. 2): S234-242.
10. Miyazaki Y., Matsuda M., DeFronzo R.A.: Dose-Response Effect of Pioglitazone on Insulin Sensitivity and Insulin Secretion in Type 2 Diabetes Diabetes Care 2002; 25: 517-523.
11. Wallace T.M., Levy J.C., Matthews D.R.: An increase in insulin sensitivity and basal β-cell function in diabetic subjects treated with pioglitazone in a placebo-controlled randomized study. Diabet. Med. 2004; 21: 568-76.
12. Aronoff S., Rosenblatt S., Braithwaite S. et al.: Pioglitazone Hydrochloride Monotherapy Improves Glycemic Control in the Treatment of Patients With Type 2 Diabetes. Diabetes Care 2000; 23: 1605-1611.
13. Göke B.: Improved glycemic control and lipid profile in a randomized study of pioglitazone compared with acarbose in patients with type 2 diabetes mellitus. Treat. Endocrinol. 2002; 1(5): 329-36.
14. Pavo I., Jermendy G., Varkonyi T.T. et al.: Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 2003; 88(4): 1637-45.
15. Charbonnel B.H., Matthews D.R., Schernthaner G. et al.: A long term comparison of pioglitazone and gliclazide in patients with type 2 diabetes mellitus: a randomized, double-blind, parallel- group comparison trial. Diabet. Med. 2005; 22(4): 399-405.
16. Pfützner A., Marx N., Lübben G. et al.: Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the Pioneer study. J. Am. Coll. Cardiol. 2005; 45(12): 1925-31.
17. Einhorn D., Rendell M., Rosenzweig J. et al.: Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group. Clin. Ther. 2000; 22(12): 1395-409.
18. Kipnes M.S., Krosnick A., Rendell M.S. et al.: Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am. J. Med. 2001; 111(1): 10-7.
19. Mattoo V., Eckland D., Widel M. et al.: Metabolic effects of pioglitazone in combination with insulin in patients with type 2diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study. Clin. Ther. 2005; 27: 554-67.
20. Goldberg R.B., Kendall D.M., Deeg M.A. et al.: A Comparison of Lipid and Glycemic Effects of Pioglitazone and Rosiglitazone in Patients With Type 2 Diabetes and Dyslipidemia. Diabetes Care 2005; 28: 1547-1554.
21. Promrat K., Lutchman G., Uwaifo G.I. et al.: A Pilot Study of Pioglitazone Treatment for Nonalcoholic Steatohepatitis. Hepatology 2004; 39: 188-196.
22. Yki-Järvinen H.: Thiazolidinediones and the liver in humans. Curr. Opin. Lipidol. 2009; 20(6): 477-83.
23. Naoumova P.R., Kindler H., Leccisotti L.: Pioglitazone Improves Myocardial Blood Flow and Glucose Utilization in Nondiabetic Patients With Combined Hyperlipidemia. JACC 2007; 50: 2051-8.
24. Derosa G.: Efficacy and Tolerability of Pioglitazone in Patients with Type 2 Diabetes Mellitus Comparison with Other Oral Antihyperglycaemic Agents. Drugs 2010; 70(15): 1945-1961.
25. Erdmann E., Spanheimer R., Charbonnel B.: Pioglitazone and the risk of cardiovascular events in patients with Type 2 diabetes receiving concomitant treatment with nitrates, renin–angiotensin system blockers, or insulin: results from the PROactive study (PROactive 20). Journal of Diabetes 2010; 2(3); 212-220.
26. Lincoff A.M., Wolski K., Nicholls S.J. et al.: Pioglitazone and Risk of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus A Meta-analysis of Randomized Trials JAMA. 2007; 298(10): 1180-1188.
27. Lewis J.D., Ferrara A., Peng T. et al.: Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone. Diabetes Care 2011; 34: 916-922.
28. Stanowisko FDA w sprawie ryzyka raka pęcherza moczowego związanego ze stosowaniem pioglitazonu [online].
29. Opinia EMA w sprawie stosowania pioglitazonu i związanym z tym ryzykiem raka pęcherza moczowego [online].
30. Nathan D.M., Buse J.B., Davidson M.B. et al.: Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193-203.
2. Wittek A., Sokalski B., Grzeszczak W. et al.: Prevalence of Diabetes and Cardiovascular Risk Factors of Industrial Area in Southern Poland. Exp. Clin. Endocrinol. Diabetes 2009; 117: 350-353.
3. De Fronzo R.A.: From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes. Mellitus Diabetes 2009; 58: 773-795.
4. Sieradzki J.: Cukrzyca. Via Medica 2006.
5. Moczulski D.: Diabetologia. Medical Tribune 2010.
6. Questions and answers on the suspension of rosiglitazone-containing medicines [online].
7. Yki-Järvinen H.: Thiazolidinediones. N. Engl. J. Med. 2004; 351(11): 1106-18.
8. Hallakou S., Doare L., Foufelle F. et al.: Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat. Diabetes 1997; 46: 1393-9.
9. Eckland D.A., Danhof M.: Clinical pharmacokinetics of pioglitazone. Exp. Clin. Endocrinol. Diabetes 2000; 108(supl. 2): S234-242.
10. Miyazaki Y., Matsuda M., DeFronzo R.A.: Dose-Response Effect of Pioglitazone on Insulin Sensitivity and Insulin Secretion in Type 2 Diabetes Diabetes Care 2002; 25: 517-523.
11. Wallace T.M., Levy J.C., Matthews D.R.: An increase in insulin sensitivity and basal β-cell function in diabetic subjects treated with pioglitazone in a placebo-controlled randomized study. Diabet. Med. 2004; 21: 568-76.
12. Aronoff S., Rosenblatt S., Braithwaite S. et al.: Pioglitazone Hydrochloride Monotherapy Improves Glycemic Control in the Treatment of Patients With Type 2 Diabetes. Diabetes Care 2000; 23: 1605-1611.
13. Göke B.: Improved glycemic control and lipid profile in a randomized study of pioglitazone compared with acarbose in patients with type 2 diabetes mellitus. Treat. Endocrinol. 2002; 1(5): 329-36.
14. Pavo I., Jermendy G., Varkonyi T.T. et al.: Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 2003; 88(4): 1637-45.
15. Charbonnel B.H., Matthews D.R., Schernthaner G. et al.: A long term comparison of pioglitazone and gliclazide in patients with type 2 diabetes mellitus: a randomized, double-blind, parallel- group comparison trial. Diabet. Med. 2005; 22(4): 399-405.
16. Pfützner A., Marx N., Lübben G. et al.: Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the Pioneer study. J. Am. Coll. Cardiol. 2005; 45(12): 1925-31.
17. Einhorn D., Rendell M., Rosenzweig J. et al.: Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group. Clin. Ther. 2000; 22(12): 1395-409.
18. Kipnes M.S., Krosnick A., Rendell M.S. et al.: Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am. J. Med. 2001; 111(1): 10-7.
19. Mattoo V., Eckland D., Widel M. et al.: Metabolic effects of pioglitazone in combination with insulin in patients with type 2diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study. Clin. Ther. 2005; 27: 554-67.
20. Goldberg R.B., Kendall D.M., Deeg M.A. et al.: A Comparison of Lipid and Glycemic Effects of Pioglitazone and Rosiglitazone in Patients With Type 2 Diabetes and Dyslipidemia. Diabetes Care 2005; 28: 1547-1554.
21. Promrat K., Lutchman G., Uwaifo G.I. et al.: A Pilot Study of Pioglitazone Treatment for Nonalcoholic Steatohepatitis. Hepatology 2004; 39: 188-196.
22. Yki-Järvinen H.: Thiazolidinediones and the liver in humans. Curr. Opin. Lipidol. 2009; 20(6): 477-83.
23. Naoumova P.R., Kindler H., Leccisotti L.: Pioglitazone Improves Myocardial Blood Flow and Glucose Utilization in Nondiabetic Patients With Combined Hyperlipidemia. JACC 2007; 50: 2051-8.
24. Derosa G.: Efficacy and Tolerability of Pioglitazone in Patients with Type 2 Diabetes Mellitus Comparison with Other Oral Antihyperglycaemic Agents. Drugs 2010; 70(15): 1945-1961.
25. Erdmann E., Spanheimer R., Charbonnel B.: Pioglitazone and the risk of cardiovascular events in patients with Type 2 diabetes receiving concomitant treatment with nitrates, renin–angiotensin system blockers, or insulin: results from the PROactive study (PROactive 20). Journal of Diabetes 2010; 2(3); 212-220.
26. Lincoff A.M., Wolski K., Nicholls S.J. et al.: Pioglitazone and Risk of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus A Meta-analysis of Randomized Trials JAMA. 2007; 298(10): 1180-1188.
27. Lewis J.D., Ferrara A., Peng T. et al.: Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone. Diabetes Care 2011; 34: 916-922.
28. Stanowisko FDA w sprawie ryzyka raka pęcherza moczowego związanego ze stosowaniem pioglitazonu [online].
29. Opinia EMA w sprawie stosowania pioglitazonu i związanym z tym ryzykiem raka pęcherza moczowego [online].
30. Nathan D.M., Buse J.B., Davidson M.B. et al.: Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193-203.